Matthias König: Developing an Open Whole-Body PBPK/PD Digital Twin of Apixaban
Matthias König, Associate Professor of Pharmacoepidemiology and Data Science at University of Southern Denmark, shared a post on LinkedIn about a recent preprint, he and his colleagues co-authored, published in Preprints.org, adding:
“New preprint: ‘An Open and Reproducible Digital Twin for Personalised Anticoagulant Therapy: Modelling Apixaban Pharmacokinetics and Pharmacodynamics.’
In this work, we developed an open whole-body PBPK/PD digital twin of the direct oral anticoagulant apixaban, linking drug exposure to anticoagulation-related pharmacodynamic endpoints, including INR, PT, mPT, aPTT, and anti-Xa activity.
The model was built and evaluated using data from 35 curated clinical PK/PD studies, covering diverse dosing regimens and clinically relevant scenarios, including renal and hepatic impairment, food intake, and body weight effects.
It captures apixaban pharmacokinetics and pharmacodynamics across these populations and provides a reusable framework for personalised anticoagulant therapy.
A key focus was reproducibility and openness: all models, simulation workflows, documentation, and curated datasets are openly available and FAIR-compliant, enabling transparent reuse, independent verification, and future extension.
The work was developed as part of the Berlin University Alliance (BUA) X-Student Research Group ‘Digital Twins in Action:
Optimizing Direct Oral Anticoagulant Use’, funded by the Bundesministerium für Bildung und Forschung (BMBF) and the State of Berlin as part of the Excellence Strategy of the Federal and State Governments.”
Title: An Open and Reproducible Digital Twin for Personalised Anticoagulant Therapy: Modelling Apixaban Pharmacokinetics and Pharmacodynamics
Authors: Mariia Myshkina, Mariia Babaeva, Linh Chang Nguyen, Shelee Bedón, Johannes Metternich, Michelle Elias, Matthias König
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy